VivoSeq
Other

PD-1

0

Pipeline Programs↗

0

Active Trials↗

1

Companies Involved↗

PD-1 is an early-stage landscape with 0 programs across 1 company. The most active players are Regeneron.

Intelligence

Pipeline Metrics

Competitive Density

0/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

33/100

Attrition Rate

29/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Regeneron logo

Regeneron

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

7

clinical trials

Unknown status4 · 57%
Withdrawn2 · 29%
Completed1 · 14%

Clinical Trials

Trial Activity

7 trials

Foundation and Clinical About the Expression of PD-1 in Peripheral Blood T Lymphocytes
Completed·—·Phase 2·NCT05792995·80 enrolled
Sargramostim (GM-CSF) + PD-1
Withdrawn·—·Phase 2·NCT04703426
Companion Study for Patients Who Completed Participation in a REGN2810 (Anti-PD-1) Clinical Study
Withdrawn·Regeneron logoRegeneron·Phase 1·NCT02520245
Real World Study of Four PD-1 Agents in China
Unknown status·TThe Affiliated Hospital of Qingdao University·N/A·NCT03966456·500 enrolled
Anti-angiogenic Agents Plus Anti-PD-1 Antibodies for uHCC
Unknown status·SShanghai Zhongshan Hospital·N/A·NCT04639284·200 enrolled
The IIT Study of Evaluation of P-IL-2 Single Agent and With Anti-PD-1
Unknown status·ZZhejiang University·Phase 1·NCT05829057·10 enrolled
Nab-PCE vs PC for MM After Failure of Anti-PD-1
Unknown status·PPeking University Cancer Hospital & Institute·Phase 2·NCT03917069·145 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)